Rituxan Rituximab

RITUXAN® for Indolent Non-Hodgkin's Lymphoma (NHL)RITUXAN for Indolent Non-Hodgkin's Lymphoma (NHL)

 

How RITUXAN Can Be Used to Treat Low-grade or follicular (indolent) Non-Hodgkin's Lymphoma

Indolent NHL, also called low-grade NHL, is a slow-growing cancer. The most common type is follicular NHL. Indolent NHL is a lifelong disease. But it can be managed with treatment. And many patients live with indolent NHL for many years.

RITUXAN can be used in different ways to treat indolent or low-grade NHL. Explore this section to learn more:

 

Initial Treatment

INDICATIONS

RITUXAN® (rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

IMPORTANT SAFETY INFORMATION

RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.

Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.

Please read the Medication Guide in HTML or PDF versions for more information.